Neuropsychological spectrum in early PD: Insights from controlled and automatic behavioural regulation

D’Iorio, Alfonsina; Guida, Pasqualina; Maggi, Gianpaolo; Redgrave, Peter; Santangelo, Gabriella; Obeso, Ignacio

doi:10.1016/j.neubiorev.2021.04.003

Cited by 7 publications

(5 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A high proportion of PD patients without MCI/dementia demonstrate executive deficits following neuropsychological evaluation. These mainly involve planning and performing complex goal-directed actions, abstract thinking, inhibitory control, set-shifting, and working memory ( Foster and Hershey, 2011 ; O’Callaghan et al, 2014 ; D’Iorio et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

The assessment of executive functions to test the integrity of the nigrostriatal network: A pilot study

Ilardi¹,

Maio

Villano

et al. 2023

Front. Psychol.

View full text Add to dashboard Cite

BackgroundParkinson’s disease (PD) is a chronic neurodegenerative disorder characterized by motor and non-motor symptoms. The latter mainly include affective, sleep, and cognitive deficits. Non-demented PD patients often demonstrate impairments in several executive domains following neuropsychological evaluation. The current pilot study aims at assessing the discriminatory power of the Frontal Assessment Battery-15 (FAB15) in differentiating (i) non-demented PD patients and healthy controls and (ii) PD patients with more and less pronounced motor symptoms.MethodsThirty-nine non-demented early-stage PD patients in the “on” dopamine state (26 females, mean age = 64.51 years, SD = 6.47, mean disease duration = 5.49 years, SD = 2.28) and 39 healthy participants (24 females, mean age = 62.60 years, SD = 5.51) were included in the study. All participants completed the FAB15. Motor symptoms of PD patients were quantified via the Unified Parkinson’s Disease Rating Scale-Part III (UPDRS-Part III) and Hoehn and Yahr staging scale (H&Y).ResultsThe FAB15 score, adjusted according to normative data for sex, age, and education, proved to be sufficiently able to discriminate PD patients from healthy controls (AUC = 0.69 [95% CI 0.60–0.75], SE = 0.06, p = 0.04, optimal cutoff = 11.29). Conversely, the battery lacked sufficient discriminative capability to differentiate PD patients based on the severity of motor symptoms.ConclusionThe FAB15 may be a valid tool for distinguishing PD patients from healthy controls. However, it might be less sensitive in identifying clinical phenotypes characterized by visuospatial impairments resulting from posteroparietal and/or temporal dysfunctions. In line with previous evidence, the battery demonstrated to be not expendable in the clinical practice for monitoring the severity of PD-related motor symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

The assessment of executive functions to test the integrity of the nigrostriatal network: A pilot study

Ilardi¹,

Maio

Villano

et al. 2023

Front. Psychol.

View full text Add to dashboard Cite

show abstract

“…The influence of sex, the presence of hypertension, diabetes, RBD, and RLS, and the intake of DA, benzodiazepines, and antidepressants, reported as categorical variables (frequencies and percentages), was evaluated using risk ratio (RR). We used the random-effects model to estimate the meta-analytic results because of its appropriateness when there is variation in clinical or demographic characteristics of the sample [18][19][20].…”

Section: Discussionmentioning

confidence: 99%

“…We used the random‐effects model to estimate the meta‐analytic results because of its appropriateness when there is variation in clinical or demographic characteristics of the sample [18–20].…”

Section: Methodsmentioning

confidence: 99%

Prevalence and clinical aspects of obstructive sleep apnea in Parkinson disease: A meta‐analysis

Maggi,

Giacobbe,

Iannotta

et al. 2023

Euro J of Neurology

Self Cite

View full text Add to dashboard Cite

Background and PurposeObstructive sleep apnea (OSA) frequently occurs in Parkinson Disease (PD), probably caused by upper airway dysfunctions or shared pathogenetic mechanisms. OSA may precede PD diagnosis or worsen throughout its course, but its relationship with clinical features and dopaminergic medication remains unclear. This meta‐analysis aimed to provide a reliable estimate of OSA prevalence in the PD population (PD‐OSA) and to clarify its clinical associated factors to help clinicians in understanding the underlying pathophysiological mechanisms.MethodsA systematic literature search was performed up to April 2023 using the PubMed, Scopus, and PsycINFO databases. Articles were included if they provided data on PD patients with and without OSA. Pooled prevalence for PD‐OSA was calculated using the proportions of PD participants diagnosed with OSA. Demographic and clinical features associated with PD‐OSA were explored by comparing PD patients with and without OSA.ResultsSeventeen studies were included in the meta‐analysis. Pooled OSA prevalence was 45% of a total sample of 1448 PD patients and was associated with older age, male sex, higher body mass index (BMI), more severe motor disturbances and periodic limb movements, reduced risk of rapid eye movement sleep behavior disorder, intake of dopamine agonists, and worse excessive daytime sleepiness. No relationship emerged with cognitive functioning and neuropsychiatric manifestations.ConclusionsOSA affects nearly half of PD patients as a secondary outcome of predisposing factors such as older age and higher BMI in addition to PD‐related motor impairment. Future studies should focus on determining the impact of both clinical features and dopaminergic medication on the development of PD‐OSA.

show abstract

“…The severity of motor symptoms is related to disease progression, alterations in neurotransmitter balance, and drug treatment [ 6 ]. Alongside the cardinal symptoms of PD, a set of non-motor signs and symptoms, including cognitive impairment, autonomic dysfunction, sleep disturbances, and affective and behavioral disorders (i.e., apathy, depression, and anxiety), is equally disabling and affects QoL [ 7 , 8 , 9 , 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

Effects of Biodanza® SRT on Motor, Cognitive, and Behavioral Symptoms in Patients with Parkinson’s Disease: A Randomized Controlled Study

Vitale,

Rosa,

Agosti

et al. 2024

JPM

Self Cite

View full text Add to dashboard Cite

Rolando Toro’s Biodanza (SRT) is a therapeutic strategy that uses movement, music, and emotions to induce integrative living experiences. The present study aims to explore the efficacy of a three-month SRT intervention on motor, cognitive, and behavioral symptoms in patients with Parkinson’s disease (PD). This study employed a randomized between-group design. Twenty-eight non-demented PD patients were enrolled in this study. Out of these, fourteen patients were assigned to the active treatment group using the Biodanza SRT system and fourteen to the untreated control group. The study group attended 2 h SRT classes once a week, completing twelve lessons in twelve weeks. All patients underwent: (i) a neurological examination to measure the severity of motor symptoms, balance, mobility, and risk of falls, and (ii) a neuropsychological battery to assess cognitive status, apathy, depressive symptomatology, and perceived quality of life (QoL), at study entry (T0) and at twelve weeks (T1, end of dance training). At T1, we observed a significant improvement in motor (i.e., severity of motor symptoms and balance) and cognitive parameters (i.e., working memory and delayed verbal memory) in all treated patients compared with the controls. Furthermore, a significant improvement in the social support dimension was found in all treated patients compared to the controls. A trend toward increased apathy was found in untreated patients at T1. The three-month Biodanza intervention significantly ameliorated the motor parameters of PD patients, with a parallel improvement in cognitive and QoL status. Hence, Biodanza intervention can, in the short term, represent a useful personalized medical intervention for the management of Parkinson’s disease.

show abstract

Neuropsychological spectrum in early PD: Insights from controlled and automatic behavioural regulation

Cited by 7 publications

References 98 publications

The assessment of executive functions to test the integrity of the nigrostriatal network: A pilot study

The assessment of executive functions to test the integrity of the nigrostriatal network: A pilot study

Prevalence and clinical aspects of obstructive sleep apnea in Parkinson disease: A meta‐analysis

Effects of Biodanza® SRT on Motor, Cognitive, and Behavioral Symptoms in Patients with Parkinson’s Disease: A Randomized Controlled Study

Contact Info

Product

Resources

About